Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (4)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Fizazi, K.
Right arrow Articles by Logothetis, C. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fizazi, K.
Right arrow Articles by Logothetis, C. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 13:187-189, 2002
© 2002 European Society for Medical Oncology

Editorial

Germ-cell tumor survivors: the price for cure

K. Fizazi, I. Chen and C. J. Logothetis

Institut Gustave Roussy, Villejuif, France and University of Texas, M.D. Anderson Cancer Center, Houston, TX, USA

Treatment integrating chemotherapy, surgery and radiotherapy results in a high cure rate in patients with disseminated germ-cell tumors (GCTs). According to the International Germ Cell Cancer Collaborative Group (IGCCCG) classification, a cure can be achieved in 92, 80 and 48% of good, intermediate and poor prognosis non-seminomatous GCT (NSGCT), respectively, and in 86 and 72% of good and intermediate prognosis seminomas, respectively [1]. Studies performed in the 1990s have shown that even higher cure rates can be achieved, although there has been no demonstration of a better treatment than bleomycin, etoposide and cisplatin (BEP) in NSGCT [2–4]. Ideally, the early identification of patients who are not likely to be cured by standard therapy would allow the use of an alternative therapy (albeit with a potentially higher toxicity than BEP) for this very select population of patients. Although we can anticipate that new biological tools . . . [Full Text of this Article]

References


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
H. J. Schmoll, R. Souchon, S. Krege, P. Albers, J. Beyer, C. Kollmannsberger, S. D. Fossa, N. E. Skakkebaek, R. de Wit, K. Fizazi, et al.
European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG)
Ann. Onc., September 1, 2004; 15(9): 1377 - 1399.
[Abstract] [Full Text] [PDF]